Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™
Status:
Completed
Trial end date:
2019-09-19
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to investigate the safety and tolerability of a single
dose of Cu-64 SARTATE and multiple doses of Cu-67 SARTATE administered to participants with
meningioma. All participants in this study will be injected with a single dose of Cu-64
SARTATE to demonstrate how it is absorbed in the body. Then participants will receive
individualised doses of Cu-67 SARTATE for up to 4 cycles.